Jenny Ko, PharmD

All articles by Jenny Ko, PharmD

In Patients With Cancer and Venous Thromboembolism, Tinzaparin Found to Be Safe, Effective, for Initial Treatment, Secondary Prophylaxis

A prospective phase 2 study of the low-molecular-weight heparin (LMWH) tinzaparin for initial treatment and secondary prophylaxis of venous thromboembolism (VTE) associated with cancer treatment found the agent to be safe and efficacious, with the recurrent VTE event rate comparing favorably with that reported for another LMWH, dalteparin according to a study presented at the 52nd American Society of Hematology Meeting and Exposition.

Randomized Trials Needed to Determine Benefit of Thromboprophylaxis in Patients With Multiple Myeloma Receiving Thalidomide- or Lenalidomide-Based Regimens

Patients with newly diagnosed or previously treated multiple myeloma (MM) who receive thalidomide (T)- or lenalidomide (L)-based regimens are at high risk of venous thromboembolism (VTE), and it is uncertain whether thromboprophylaxis provides a clear benefit, especially in those who receive L-based therapy or have previously treated disease, according to results of a systematic review and meta-analysis that were shown at the 52nd American Society of Hematology Meeting and Exposition.